About the Company
We do not have any company description for VACCINEX, INC. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VCNX News
Vaccinex, Inc. (VCNX)
On February 6, 2024, the firm acquired 1,631,648 shares of Vaccinex Inc, marking a new holding in its investment portfolio. The shares were purchased at a price of $0.5863 each, reflecting a ...
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company ...
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D).
Vaccinex, Inc. (VCNX) Interactive Stock Chart - Yahoo Finance
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D ...
VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
Vaccinex just reported results for the fourth quarter of 2023.More From InvestorPlace The #1 AI Investment Might Be This ...
Vaccinex Inc VCNX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a ...
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and ...
Vaccinex, Inc.: Vaccinex Reports 2023 Financial Results and Provides Corporate Update
About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D).
Loading the latest forecasts...